Monthly Prescribing Reference1d
FDA Approves Merilog, a Rapid-Acting Insulin Biosimilar Product
Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.
The American Journal of Managed Care1d
Positioning Biosimilars in Clinical Practice
Panelists discuss how biosimilars are gaining traction through targeted education, cost-effectiveness analysis, and rigorous ...
centerforbiosimilars4d
The Top 5 Biosimilar Articles for the Week of February 17
Number 4: The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis ...
Wyoming News5d
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
The U.S. Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) ...
Managed Healthcare Executive6d
FDA Approves First Biosimilar of Novolog
Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...
Capital Public Radio6d
State insulin program still has no firm timeline
“Our internal and external experts all believe that the implementational time frame, while not as fast as we had hoped, are ...
Interesting Engineering on MSN6d
FDA approves first-ever rapid-acting insulin biosimilar for diabetes treatment
First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...